EN DE
Watch Inoviq Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Inoviq Ltd (IIQ) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Inoviq Ltd stock A$0.06, price A$0.13, that is 54.2% below the price, quality 28 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000196149

IL Inoviq Ltd logo Thin data Nov 5, 2026

Inoviq Ltd

IIQ · AU
Very expensive, weak quality

Our calculation puts a fair price 54% below what the stock costs today.

Fair value A$0.0595 · Strongly overvalued
Quality 28/100
Weak Growth (revenue 5y −19.4 %/yr in AUD)
Negative free cash flow
Trails peers (2/7)
Narrow moat 10/100 · thin data
Thin data
⚠ Dilution
Watch Inoviq Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$1.86 A$0.1300 Fair Value A$0.0595 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range A$0.1300 – A$1.86 · fair‑value band A$0.0425 – A$0.0765 · the A$0.1300 price screens above the A$0.0595 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Inoviq in your weekly email

Every Wednesday you see whether Inoviq is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States.

Show moreShow less

It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development.

It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases.

The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.

Stock analysis

Inoviq Ltd (IIQ) currently trades at A$0.1300, while our model-based Fair Value estimate is A$0.0595, 54% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: A$0.0425 (bear) to A$0.0765 (bull), the price of A$0.1300 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Inoviq Ltd reported revenue of A$432K in FY2026 versus A$277K in FY2022, a compound +11.8%/yr. Reported net income was −A$7.5M in FY2026.

Key figures

Market cap A$18.3M (≈ $12.6M) Micro · P/S ratio 8.58 · EPS (TTM) A$−0.0600 · Return on equity −42.2% · Return on assets (EBIT) −43.7% (5-year average) · Operating margin −344% · Revenue growth (YoY) +11.3% · Free cash flow −A$6.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 76% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at −54%, IIQ screens richer than that median.

Fair Value models

Bear A$0.0425 Fair Value A$0.0595 Bull A$0.0765
Price A$0.1300 · Downside -54.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) A$0.0500 A$0.0700 A$0.0900 52
All 1 models by family
Asset-Based
NCAV (Graham) A$0.0500 A$0.0700 A$0.0900 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 14
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 81
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 12
How calm the share price moves, does not count
Price momentum 3
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−76.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.4%
Start year 2021 (pandemic)
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−794.7% (2021) → −2,237.4% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

IIQ screens overvalued: fair value 54% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Inoviq Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −54.2% · Below median
Profitability
Return on assets −36.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 11.3% · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.97× · Cheapest 25%
P/S (12 months) 8.27× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)57 · sector 39
PAST (return on equity)0 · sector 15
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥147.00 ¥164.66 +12% vs IIQ
IQVIA Holdings IQV $271.83 $299.01 +10% vs IIQ
Illumina, Inc ILMN $213.13 $234.44 +10% vs IIQ
Thermo Fisher Scientific Inc TMO $694.76 $686.04 −1% vs IIQ
Danaher Corporation DHR $230.25 $209.18 −9% vs IIQ
IDEXX Laboratories, Inc IDXX $676.04 $496.48 −27% vs IIQ
Mettler-Toledo International Inc MTD $1,722 $655.06 −62% vs IIQ
Agilent Technologies, Inc A $174.76 $64.53 −63% vs IIQ
Lonza Group LONN CHF 663.40 CHF 153.50 −77% vs IIQ
Waters Corporation WAT $457.60 $91.26 −80% vs IIQ

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Inoviq Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Inoviq Ltd Fair Value". https://www.fairvalue-calculator.com/stock/IIQ

Frequently asked questions

Is Inoviq Ltd (IIQ) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of A$0.0595 versus a price of A$0.1300, about 54% lower (overvalued).
What is the fair value of IIQ?
Our model-based fair value for Inoviq Ltd is A$0.0595 (as of Nov 5, 2026), built from audited fundamentals. The current price: A$0.1300.
What is the quality score of IIQ?
Inoviq Ltd has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Inoviq Ltd (IIQ)?
Our model-based price target is the fair value of A$0.0595 (as of Nov 5, 2026) from 1 valuation models. Cautious scenario A$0.0425, optimistic scenario A$0.0765. It is a calculation from audited fundamentals, not an analyst target.
What is the Inoviq Ltd stock forecast for 2026?
Our models put fair value at A$0.0595, about 54% lower versus a price of A$0.1300 (overvalued). Cautious scenario A$0.0425, optimistic scenario A$0.0765. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Inoviq Ltd (IIQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Inoviq Ltd it is A$0.0595 per share (as of Nov 5, 2026), against a price of A$0.1300. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Inoviq Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, IIQ trades above its calculated fair value: price A$0.1300, fair value A$0.0595, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IIQ?
No. The price is what the market pays today (A$0.1300); the fair value is what the company's own numbers justify (A$0.0595). For Inoviq Ltd the two are A$0.0705 per share apart. That gap is exactly why we show both numbers side by side.
How much is Inoviq Ltd worth?
The market values Inoviq Ltd at about A$18.3M (market capitalisation, as of Nov 5, 2026). Per share that is A$0.1300; our models calculate a fair value of A$0.0595 per share.
What do the bullish and bearish scenarios say about IIQ?
Our models span a range for Inoviq Ltd: cautious scenario A$0.0425, base A$0.0595, optimistic A$0.0765 per share (as of Nov 5, 2026, price A$0.1300). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Inoviq Ltd (IIQ)?
Balance-sheet figures for Inoviq Ltd (as of Nov 5, 2026): return on equity −42.2%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is IIQ from its 52-week high?
Inoviq Ltd trades at A$0.1300, about 76% below its 52-week high of A$0.5450 and at the low of A$0.1300 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0595 is for.
Which stocks are comparable to Inoviq Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Inoviq Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price A$0.1300, calculated fair value A$0.0595 (−54%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IIQ calculated?
We run Inoviq Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of A$0.0595 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Inoviq Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Inoviq Ltd (IIQ)?
The closing price on Nov 9, 2026 was A$0.1300. Our model-based fair value is A$0.0595, about 54% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Inoviq Ltd right now?
The price sits above even our optimistic bull case (A$0.0765). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Inoviq Ltd

How large is the market capitalisation of Inoviq Ltd (IIQ)?
The market capitalisation of Inoviq Ltd is A$18.3M (≈ $12.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Inoviq Ltd (IIQ)?
The price-to-sales ratio of Inoviq Ltd is 8.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Inoviq Ltd (IIQ)?
Earnings per share at Inoviq Ltd are A$−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Inoviq Ltd (IIQ)?
The return on equity (ROE) of Inoviq Ltd is −42.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Inoviq Ltd (IIQ)?
On an EBIT basis the return on assets of Inoviq Ltd is −43.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Inoviq Ltd (IIQ)?
The operating margin of Inoviq Ltd is −344% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Inoviq Ltd (IIQ)?
Revenue at Inoviq Ltd is growing +11.3% versus a year earlier (3y avg +2.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Inoviq Ltd (IIQ) generate?
The free cash flow of Inoviq Ltd is −A$6.5M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Inoviq Ltd (IIQ) hold?
Inoviq Ltd holds more cash than debt, A$9.1M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Inoviq Ltd in the live analysis

One click puts Inoviq Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.